glp 1 agonists on the market GLP-1 Receptor Agonist Size & Analysis, 2026-2033 Market Overview: GLP-1 Agonists and

The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031

Effectiveness and Impact Significant Weight Loss: Phase 2 studies showed up to roughly 20% average body weight loss at 52 weeks in participants with obesity

Explore the mechanisms, clinical applications, and future opportunities of GLP-1 receptor agonists in drug development and disease management.

22, 2025, when the U.S Food and Drug Administration (FDA) approved oral Wegovy by Novo Nordisk as the first daily, oral GLP-1 pill for weight management.

IntroductionGlucagon-like peptide-1 receptor agonists (GLP-1 RA) are novel agents with proven cardiovascular (CV) benefits

Discover the U.S